Evoke Pharma, Inc., a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office (USPTO) issued US Patent No. 11,813,231 titled “Nasal Formulations of Metoclopramide”, pertaining to the company’s commercially available and FDA-approved nasal formulation of metoclopramide, Gimoti.
This new patent, issued on November 14, 2023, provides Evoke with additional intellectual property protections with claims to metoclopramide being delivered intranasally, amongst others. Evoke continues to see significant commercial value, particularly with the rising popularity of GLP-1 agonist medications for diabetes which are potentially unmasking gastroparesis (stomach paralysis) in larger groups of patients. Gimoti is the only outpatient, non-oral drug labelled for the treatment of acute and recurrent diabetic gastroparesis. The ability to take the medication non-orally is important as gastroparesis causes tablets to be unpredictably absorbed. Pills may linger in the stomach instead of being passed into the intestines for absorption or not absorbed at all due to one of the key symptoms of the disease, vomiting.
“We continue to witness the significance of Gimoti in the marketplace through various validation points, including patient and market data, growing revenues, and a robust stream of patent protections. We are thrilled to continue providing patients a life-changing experience with diabetic gastroparesis treatment and bolster the already promising commercial opportunity for Gimoti,” commented Matt D’Onofrio, president and COO of Evoke Pharma.
Gimoti is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
